Obermatt

Flags

Earnings warning

MediciNova

NMQ:MNOV · US58468P2065
BiotechnologyX-Small

360

21
Profit price79
Owner Earnings Yield1
Dividend Yield1
Price/Sales22
EV / Gross Profit1
Price/Book51
Return on Capital76
Cash Return on Capital85
Return on Equity81
Profit margins32
Accruals32
Owner Earnings Margin22
Sales growth42
Profit growth79
Reinvestment8
Price momentum25
Debt load91
Refinancing35
Debt Payback1
Liquidity54
Analyst ratings37
Expectations trend5
Market mood13
Value Creation6/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

MediciNova doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeX-Small
TypePublic Company
ExchangeNASDAQGM
Founded2000
Employees10
ISINUS58468P2065
Last UpdateApr 2, 2026
Themes
ImmunologyNeurologyAddictionInflammationCentral Nervous SystemRespiratoryNeuroscienceHepatologyOncologyBiotechnologyPharmaceuticalTherapeutics

Description

MediciNova, Inc. operates as a biopharmaceutical company. The company focuses on developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. The company's st…

Analysis

Hope premium

MediciNova, Inc. is priced well ahead of what the underlying numbers justify, a pattern we describe as a hope premium. Worth noting: the cash the business generates has lagged behind what the income statement shows.

Valuation data is not available for this company.

Growth is moderate; the safety picture is stretched. The company scores 6/20 on our value-creation score: not creating value.

Flags to be aware of: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
1
2026

All-time high

8

Mar 2026

All-time low

1

Jun 2026

Average rank

5

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
22
Price/Earnings
54
Price/Book
51
Dividend Yield
1
Value (overall)
20

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare MediciNova with its peers
Kymera Therapeutics
NMQ:KYMR
30
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Sagimet Biosciences
NMQ:SGMT
59
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Galectin Therapeutics
NAQ:GALT
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Soleno Therapeutics
NAQ:SLNO
67
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Seres Therapeutics
NSQ:MCRB
6
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Madrigal Pharmaceuticals
NSQ:MDGL
67
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →